According to the current analysis of Emergen Research, the Metastatic urothelial carcinoma market was valued at USD 725.9 million in 2019 and is expected to reach USD 2.71 billion by the year 2027, at a CAGR of 17.9%.
According to the current analysis of Emergen Research, the Metastatic urothelial carcinoma market was valued at USD 725.9 million in 2019 and is expected to reach USD 2.71 billion by the year 2027, at a CAGR of 17.9%. The global metastatic urothelial carcinoma market is primarily driven by the rise in incidents of bladder cancer and the availability of effective treatments. According to a report published by the National Cancer Institute in September 2019, it was estimated that there will be 81,400 new cases of bladder cancer in the United States in 2019. Bladder cancer is the fourth most common cancer in men and the ninth most common cancer overall. The report also stated that an estimated 17,670 people are expected to die of bladder cancer in 2019.
The increase in incidents of bladder cancer is primarily attributed to the use of tobacco products, such as cigarettes and cigars. According to the World Health Organization (WHO), tobacco use is the single most preventable cause of death globally and is responsible for 10% of all adult male deaths and 6% of all adult female deaths. Moreover, according to a report published by the American Cancer Society in March 2019, it was estimated that approximately 50,030 people in the United States would die from bladder cancer in 2019.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/48
The other factor driving the growth of the metastatic urothelial carcinoma market is the availability of effective treatments. According to a report published by the National Cancer Institute in September 2019, there are several treatment options available for patients with bladder cancer, including surgery, chemotherapy, radiation therapy, and immunotherapy.
The market is also expected to be triggered by factors such as technological advancement and the increasing number of urology centers. The market faces some major challenges such as the lack of awareness and skilled medical personnel.
However, the high cost of treatment is expected to restraint the growth of the metastatic urothelial carcinoma market. According to a report published by the American Cancer Society in March 2019, the average cost of treatment for bladder cancer is approximately USD 64,000.
Further key findings from the report suggest
- In September 2019, Astellas Pharma Inc. announced that the U.S Food and Drug Administration (FDA) approved Enfortumab vedotin-ejfv (Padcev), an antibody-drug conjugate (ADC) for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have previously received a programmed cell death receptor-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.The company’s product, Padcev is the first and only ADC that targets Nectin-4, which is highly expressed in urothelial cancer cells.
- The Drug segment is expected to register the fastest revenue CAGR during the forecast period. The Metastatic urothelial carcinoma Market by drug type segment includes chemotherapy and targeted therapy. Chemotherapy held the largest market share in 2016 due to the large number of ongoing clinical trials and FDA approvals for this drug class.
- Targeted therapy is expected to grow at a rapid pace during the forecast period, owing to the launch of new targeted therapies and the high unmet need in this disease indication. The target therapy drugs segment is further classified into checkpoint inhibitors, mTOR inhibitors, angiogenesis inhibitors, PARP inhibitors, and others (progestin receptor modulators (PRMs) and hedgehog pathway inhibitors).
- The chemotherapy segment is expected to register the fastest revenue CAGR during the forecast period due to the high recurrence rate of the disease and rising preference for targeted therapies.
- The immunotherapy and biologics segment is expected to grow at a significant rate during the forecast period due to the increasing preference for biologics and immunotherapy treatment. According to a study published by the American Cancer Society in 2019, it is estimated that there will be 81,400 new cases of bladder cancer in the United States.
- The Hospital segment is expected to grow at a significant rate during the forecast period due to the increasing number of urothelial carcinoma cases. According to the American Cancer Society, in 2019, there will be an estimated 81,400 new cases of bladder cancer diagnosed and 17,980 deaths from bladder cancer.
- The Outpatient segment is expected to grow at a significant rate during the forecast period due to its cost-effectiveness and less time-consuming procedures.This report studies the global Metastatic Urothelial Carcinoma market size, industry status and forecast, competition landscape and growth opportunity.
- The Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period due to the rising prevalence of bladder cancer and increasing government initiatives for cancer awareness in this region.
- North American segment held the largest share in the industry owing to the rising number of approvals and the presence of key players in this region. Also, increasing government support for the development of new therapeutics and therapies is anticipated to propel market growth in North America.
- Key participants in the market include Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, and Pfizer.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/metastatic-urothelial-carcinoma-market
For the purpose of this report, Emergen research has segmented the Metastatic urothelial carcinoma market on the basis of treatment, diagnosis, end use and region:
By Treatment Outlook (Revenue in Million USD; 2017-2027)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Intravesical Therapy
By Diagnosis Outlook (Revenue in Million USD; 2017-2027)
- Urine Lab Tests
- Cystoscopy
- Intravenous pyelogram (IVP)
- Biopsy
By End Use Outlook (Revenue in Million USD; 2017–2027)
- Hospital
- Oncology Clinics
- Research Institutes
- Others
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- US.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/48
Explore More Reports Emergen Research:
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-metastatic-urothelial-carcinoma-market
